BRCA1-associated growth arrest is RB-dependent

Olga Aprelikova, Bruno Fang, Eric G. Meissner, +6

Proceedings of the National Academy of Sciences

BRCA1 Is a Selective Co-activator of 14-3-3ς Gene Transcription in Mouse Embryonic Stem Cells

Olga Aprelikova, Amy J. Pace, Bruno Fang, +2

Journal of Biological Chemistry

[⁶⁸Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [¹⁷⁷Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy.

Phillip H. Kuo, Jacob Hesterman, Kambiz Rahbar, +12

Journal of Clinical Oncology

Oncologic ImagingPsma UptakePet-mriMultimodalityTreatment Verification +21

Quantitative ⁶⁸Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following ¹⁷⁷Lu-PSMA-617 (VISION Trial)

Phillip H. Kuo, Michael J. Morris, Jacob Hesterman, +20

Radiology

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)

Neeraj Agarwal, Bradley A. McGregor, Benjamin L. Maughan, +16

The Lancet Oncology

UrologyGenitourinary CancerMedicinePharmacologyClinical Trials +7

Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.

Joel W. Neal, Farah Louise Lim, Enriqueta Felip, +9

Journal of Clinical Oncology

ImmunologyImmunoeditingPathologyPharmacotherapyImmunotherapeutics +23

Real-World Ibrutinib dose Reductions, Holds and Discontinuations in Chronic Lymphocytic Leukemia

Jing‐Zhou Hou, Kellie Ryan, Senxi Du, +7

Future Oncology

Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non–Small Cell Lung Cancer

Matthew P. Deek, Sinae Kim, Inaya Ahmed, +5

American Journal of Clinical Oncology

Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.

Joel W. Neal, Armando Santoro, Santiago Viteri, +13

Journal of Clinical Oncology

ImmunologyImmunoeditingImmunotherapeuticsImmunotherapyOncology +16

390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial

Erika Hamilton, Hyo S. Han, Anne F. Schott, +16

Annals of Oncology

Endocrine OncologyBreast OncologyOncologyMedicineHormonal Receptor +9